Stratatech says its genetically -engineered skin substitute passed its Phase II clinical trial as a treatment for severe burns.
Wisconsin's Stratatech said its biologically active, genetically engineered skin substitute passed a Phase II clinical trial as a treatment for severe burns, setting the stage for a bid for a Phase III trial.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1L4hohb
Cap comentari:
Publica un comentari a l'entrada